Trials / Completed
CompletedNCT01594957
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of hepatic impairment to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCQ908 | Participants will receive a single oral dose of LCQ908 |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-05-09
- Last updated
- 2020-12-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01594957. Inclusion in this directory is not an endorsement.